Jason Wing

发表

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience

R. Kurzrock, E. Capparelli, M. Nikanjam, 2018, Cureus.

Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

M. Heinrich, A. Palumbo, Jason Wing, 2020, Leukemia & lymphoma.